Related Experiment Videos
[Apolipoprotein C-III in nephrology]
Insights
Elevated apolipoprotein C-III (apoC-III) levels in kidney disease patients correlate with hypertriglyceridemia. Understanding apoC-III metabolism is key to addressing lipid disorders in renal failure.
Area of Science:
- Biochemistry
- Nephrology
- Lipid Metabolism
Context:
- Apolipoprotein C-III (apoC-III) is a protein synthesized in the liver and small intestine.
- It plays a role in regulating triglyceride levels by inhibiting lipoprotein lipase and hepatic triglyceride lipase.
- Increased plasma apoC-III levels are observed in patients with renal failure, on hemodialysis, and post-renal transplant.
Purpose:
- To discuss the role of hormonal and non-hormonal factors in modulating apolipoprotein C-III metabolism.
- To elucidate the physiopathological mechanisms underlying lipid disorders in renal diseases.
Summary:
- Apolipoprotein C-III (apoC-III) is synthesized by the liver and small intestine and inhibits key lipases.
- Elevated plasma apoC-III levels are a characteristic finding in patients with chronic kidney disease, undergoing hemodialysis, or having received a renal transplant.
- This elevation is strongly associated with the hypertriglyceridemia commonly seen in these patient populations.
Impact:
- Provides insights into the mechanisms of dyslipidemia in renal disease.
- Highlights apolipoprotein C-III as a potential therapeutic target for managing hypertriglyceridemia in kidney patients.
- Contributes to a better understanding of lipid metabolism alterations in the context of kidney dysfunction.
Abstract:
Apolipoprotein C-III is synthesized by the liver and the small intestine. It inhibits the actions of lipoprotein lipase and hepatic triglyceride lipase. An increase of plasma apolipoprotein C-III levels has been found in patients with renal failure, in those under haemodialysis and in renal transplant recipients. The consequences of this increase correlate with the hypertriglyceridaemia observed in these patients. The responsibility of hormonal or non-hormonal factors that modulate the metabolism of apolipoprotein C-III is discussed in order to help in the understanding of the physiopathological mechanisms of lipid disorders in these renal diseases.